SCHEMBL13245284

SCHEMBL13245284

CC(C)C(C)NC(=O)C(=O)C(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.34
TAS1R1 Q7RTX1 2/20 0.34
TAS1R2 Q8TE23 2/20 0.34
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
POLB P06746 1/20 0.31
DPP4 P27487 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30
MMP8 P22894 1/20 0.30
CA9 Q16790 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13245283 0.82 TSHR (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20079481 0.76 PSEN1 (0.32) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL24567748 0.75 NPSR1 (0.37) TAS1R3TAS1R1TAS1R2POLBDPP4
SCHEMBL24571691 0.75 NPSR1 (0.37) TAS1R3TAS1R1TAS1R2POLBDPP4
SCHEMBL13245165 0.73 MMP1 (0.45) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL24364582 0.72 KDM5B (0.38) TAS1R3TAS1R1TAS1R2
SCHEMBL8300119 0.72 TAS1R3 (0.38) TAS1R3TAS1R1TAS1R2TSHR
SCHEMBL13245162 0.71 TSHR (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL25873437 0.68 TGFBR1 (0.47) TAS1R3TAS1R1TAS1R2DPP4TSHR
SCHEMBL9963462 0.68 DPP4 (0.39) TAS1R3TAS1R1TAS1R2POLBDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100173851-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2010-07-08 US disclosed
US-20070292933-A1 Inhibitors of serine proteases, particular HCV NS3-NS4A protease PITLIK JANOS 2007-12-20 US disclosed
US-7273885-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070292933-A1 Inhibitors of serine proteases, particular HCV NS3-NS4A protease SERPINB1, PRSS1, SPINT2 TAS1R3 4194/4885TAS1R1 4104/4885TAS1R2 4417/4885
US-20100173851-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE SERPINB1, PRSS1, SPINT2 TAS1R3 4129/4885TAS1R1 4020/4885TAS1R2 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.